Skip to main content

Table 1 Accuracy of primary data (BCQDB) in comparison to external databases, period 1996-97

From: Valid comparisons and decisions based on clinical registers and population based cohort studies: assessing the accuracy, completeness and epidemiological relevance of a breast cancer query database

 

Secondary data

Primary data

95% Confidence interval

Test-statistic

Variable-level

GER (θ1)

BCQDB (θ2)

Lower bound (θ2)

Upper bound (θ2)

p-value

00-49 years

21.4

24.4

19.4

30.1

ns

50-69 years

50.5

43.6

37.6

49.8

0.024

≥ 70 years

28.1

32.0

26.4

37.9

ns

pTis (non-invasive)

4.3

4.5

2.4

7.7

ns

pT1 (≤ 2cm)

47.4

53.0

46.8

59.1

ns

pT2 (≤ 5cm)

35.8

30.8

25.3

36.8

ns

pT3 (> 5cm)

4.7

2.6

1.1

5.3

ns

pT4 (involving other areals)

7.8

9.0

5.9

13.1

ns

pN+

37.0

32.7

27.1

38.7

ns

Involved lymph nodes 0

60.9

63.4

57.0

69.6

ns

Involved lymph nodes 1-3

20.1

19.3

14.5

24.9

ns

Involved lymph nodes 4-9

11.8

10.5

6.9

15.1

ns

Involved lymph nodes >10

7.2

6.7

3.9

10.7

ns

Stage 0

4.2

4.5

2.4

7.7

ns

Stage 1

36.0

38.7

32.8

44.9

ns

Stage 2a

28.5

27.8

22.5

33.6

ns

Stage 2b

16.4

12.0

8.4

16.6

ns

Stage 3a

4.2

2.3

0.8

4.8

ns

Stage 3b

6.3

8.6

5.6

12.7

ns

Stage 4

4.5

6.0

3.5

9.6

ns

Grading 1 (G1)

11.3

7.9

4.9

11.9

ns

Grading 2 (G2)

55.8

43.3

37.1

49.6

<0.001

Grading 3 (G3)

c32.9

48.8

42.5

55.1

<0.001

ERPR+

82.0

83.5

78.4

87.7

ns

Variable-level

GKR (θ1)

BCQDB (θ2)

Lower bound (θ2)

Upper bound (θ2)

p-value

00-49 years

20.4

24.4

19.4

30.1

ns

50-69 years

49.0

43.6

37.6

49.8

ns

≥ 70 years

30.6

32.0

26.4

37.9

ns

Left side

50.6

56.0

49.8

62.1

ns

Right side

47.7

44.0

37.9

50.2

ns

Breast quadrant I

48.6

46.6

40.5

52.8

ns

Breast quadrant II

12.3

11.3

7.7

15.7

ns

Breast quadrant III

9.1

11.7

8.1

16.1

ns

Breast quadrant IV

5.6

8.6

5.6

12.7

ns

Multifocal

16.6

17.3

12.9

22.4

ns

Mamille

7.8

4.5

2.4

7.7

0.045

Non-invasive tumor

5.8

4.5

2.4

7.7

ns

Stage 0

6.1

4.5

2.4

7.7

ns

Stage 1

38.4

38.7

32.8

44.9

ns

Stage 2

41.9

39.8

33.9

46.0

ns

Stage 3

8.0

10.9

7.4

15.3

ns

Stage 4

5.6

6.0

3.5

9.6

ns

Stage 0 | 0–49 years

7.0

7.7

2.5

17.0

ns

Stage 1 | 0–49 years

38.0

36.9

25.3

49.8

ns

Stage 2 | 0–49 years

43.7

46.2

33.7

59.0

ns

Stage 3 | 0–49 years

6.5

6.2

1.7

15.0

ns

Stage 4 | 0–49 years

4.8

3.1

0.4

10.7

ns

Stage 0 | 50–69 years

6.9

4.3

1.4

9.8

ns

Stage 1 | 50–69 years

39.4

41.4

32.3

50.9

ns

Stage 2 | 50–69 years

41.0

42.2

33.1

51.8

ns

Stage 3 | 50–69 years

7.7

6.9

3.0

13.1

ns

Stage 4 | 50–69 years

5.0

5.2

1.9

10.9

ns

Stage 0 | ≥70 years

4.1

2.4

0.3

8.2

ns

Stage 1 | ≥70 years

36.9

36.5

26.3

47.6

ns

Stage 2 | ≥70 years

42.2

31.8

22.1

42.8

ns

Stage 3 | ≥70 years

9.7

20.0

12.1

30.1

<0.001

Stage 4 | ≥70 years

7.1

9.4

4.2

17.7

ns

  1. (θ) Population parameter in percent, (GER) Mean of a five German regions for 1996–97 (Engel et al., 2002).
  2. (BCQDB) Breast Cancer Query Database, Marburg, Germany; (GKR) Common Cancer Registers of the states.
  3. Berlin, Brandenburg, Mecklenburg-Vorpommern, Saxony-Anhalt, Saxony and Thuringa (Stabenow & Eisinger, 2001).
  4. (pN+) Pathological assessment of metastases in lymph nodes, (ERPR) Estrogen-Progesterone-Receptors.
  5. (Multifocal) All quadrants involved, (Stage | age) Percent of patients with stage number conditional on age groups.